Sarcoidosis-Associated Pulmonary Hypertension

Sarcoidosis is a granulomatous disorder of unknown etiology characterized by multisystem non-caseating granulomas. Pulmonary hypertension (PH) is a well-known complication of sarcoidosis and is associated with increased morbidity and mortality. The actual epidemiology of sarcoidosis-associated PH (S...

Full description

Saved in:
Bibliographic Details
Main Authors: Yoshitaka Morimatsu, Nobuhiro Tahara, Masaki Okamoto, Munehisa Bekki, Atsuko Tahara, Yoshiko Eto, Tadahiro Kugai, Yuki Koga, Shoko Maeda-Ogata, Akihiro Honda, Sachiyo Igata, Yoshiaki Zaizen, Shuichi Tanoue, Tomoaki Hoshino, Tatsuya Ishitake, Yoshihiro Fukumoto
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/61/2/342
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850231026697109504
author Yoshitaka Morimatsu
Nobuhiro Tahara
Masaki Okamoto
Munehisa Bekki
Atsuko Tahara
Yoshiko Eto
Tadahiro Kugai
Yuki Koga
Shoko Maeda-Ogata
Akihiro Honda
Sachiyo Igata
Yoshiaki Zaizen
Shuichi Tanoue
Tomoaki Hoshino
Tatsuya Ishitake
Yoshihiro Fukumoto
author_facet Yoshitaka Morimatsu
Nobuhiro Tahara
Masaki Okamoto
Munehisa Bekki
Atsuko Tahara
Yoshiko Eto
Tadahiro Kugai
Yuki Koga
Shoko Maeda-Ogata
Akihiro Honda
Sachiyo Igata
Yoshiaki Zaizen
Shuichi Tanoue
Tomoaki Hoshino
Tatsuya Ishitake
Yoshihiro Fukumoto
author_sort Yoshitaka Morimatsu
collection DOAJ
description Sarcoidosis is a granulomatous disorder of unknown etiology characterized by multisystem non-caseating granulomas. Pulmonary hypertension (PH) is a well-known complication of sarcoidosis and is associated with increased morbidity and mortality. The actual epidemiology of sarcoidosis-associated PH (SAPH) remains unknown, and its pathogenesis has not been fully elucidated. SAPH is classified under the miscellaneous category (group 5 of the PH classification). The clinical presentation of SAPH is variable and not always proportional to the severity of sarcoidosis. Appropriate management for SAPH by an experienced physician is important; however, no treatment algorithm for SAPH has been established. Lung transplantation should be considered in refractory cases. Pulmonary arterial hypertension-specific vasodilators targeting the endothelin pathway, nitric oxide pathway, and prostacyclin pathway have improved the clinical functions and hemodynamics in some patients with SAPH.
format Article
id doaj-art-a4d947d32a0f47cbb1e209ac6c81fd94
institution OA Journals
issn 1010-660X
1648-9144
language English
publishDate 2025-02-01
publisher MDPI AG
record_format Article
series Medicina
spelling doaj-art-a4d947d32a0f47cbb1e209ac6c81fd942025-08-20T02:03:40ZengMDPI AGMedicina1010-660X1648-91442025-02-0161234210.3390/medicina61020342Sarcoidosis-Associated Pulmonary HypertensionYoshitaka Morimatsu0Nobuhiro Tahara1Masaki Okamoto2Munehisa Bekki3Atsuko Tahara4Yoshiko Eto5Tadahiro Kugai6Yuki Koga7Shoko Maeda-Ogata8Akihiro Honda9Sachiyo Igata10Yoshiaki Zaizen11Shuichi Tanoue12Tomoaki Hoshino13Tatsuya Ishitake14Yoshihiro Fukumoto15Department of Environmental Medicine, Kurume University School of Medicine, Kurume 830-0011, JapanDivision of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, JapanDepartment of Respirology, NHO Kyushu Medical Center, Fukuoka 810-0065, JapanDivision of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, JapanDivision of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, JapanDivision of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, JapanDivision of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, JapanDivision of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, JapanDivision of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, JapanDivision of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, JapanDivision of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, JapanDivision of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume 830-0011, JapanDepartment of Radiology, Kurume University School of Medicine, Kurume 830-0011, JapanDivision of Respirology, Neurology and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume 830-0011, JapanDepartment of Environmental Medicine, Kurume University School of Medicine, Kurume 830-0011, JapanDivision of Cardiovascular Medicine, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, JapanSarcoidosis is a granulomatous disorder of unknown etiology characterized by multisystem non-caseating granulomas. Pulmonary hypertension (PH) is a well-known complication of sarcoidosis and is associated with increased morbidity and mortality. The actual epidemiology of sarcoidosis-associated PH (SAPH) remains unknown, and its pathogenesis has not been fully elucidated. SAPH is classified under the miscellaneous category (group 5 of the PH classification). The clinical presentation of SAPH is variable and not always proportional to the severity of sarcoidosis. Appropriate management for SAPH by an experienced physician is important; however, no treatment algorithm for SAPH has been established. Lung transplantation should be considered in refractory cases. Pulmonary arterial hypertension-specific vasodilators targeting the endothelin pathway, nitric oxide pathway, and prostacyclin pathway have improved the clinical functions and hemodynamics in some patients with SAPH.https://www.mdpi.com/1648-9144/61/2/342sarcoidosissarcoidosis-associated pulmonary hypertensionepidemiologypathogenesistreatment
spellingShingle Yoshitaka Morimatsu
Nobuhiro Tahara
Masaki Okamoto
Munehisa Bekki
Atsuko Tahara
Yoshiko Eto
Tadahiro Kugai
Yuki Koga
Shoko Maeda-Ogata
Akihiro Honda
Sachiyo Igata
Yoshiaki Zaizen
Shuichi Tanoue
Tomoaki Hoshino
Tatsuya Ishitake
Yoshihiro Fukumoto
Sarcoidosis-Associated Pulmonary Hypertension
Medicina
sarcoidosis
sarcoidosis-associated pulmonary hypertension
epidemiology
pathogenesis
treatment
title Sarcoidosis-Associated Pulmonary Hypertension
title_full Sarcoidosis-Associated Pulmonary Hypertension
title_fullStr Sarcoidosis-Associated Pulmonary Hypertension
title_full_unstemmed Sarcoidosis-Associated Pulmonary Hypertension
title_short Sarcoidosis-Associated Pulmonary Hypertension
title_sort sarcoidosis associated pulmonary hypertension
topic sarcoidosis
sarcoidosis-associated pulmonary hypertension
epidemiology
pathogenesis
treatment
url https://www.mdpi.com/1648-9144/61/2/342
work_keys_str_mv AT yoshitakamorimatsu sarcoidosisassociatedpulmonaryhypertension
AT nobuhirotahara sarcoidosisassociatedpulmonaryhypertension
AT masakiokamoto sarcoidosisassociatedpulmonaryhypertension
AT munehisabekki sarcoidosisassociatedpulmonaryhypertension
AT atsukotahara sarcoidosisassociatedpulmonaryhypertension
AT yoshikoeto sarcoidosisassociatedpulmonaryhypertension
AT tadahirokugai sarcoidosisassociatedpulmonaryhypertension
AT yukikoga sarcoidosisassociatedpulmonaryhypertension
AT shokomaedaogata sarcoidosisassociatedpulmonaryhypertension
AT akihirohonda sarcoidosisassociatedpulmonaryhypertension
AT sachiyoigata sarcoidosisassociatedpulmonaryhypertension
AT yoshiakizaizen sarcoidosisassociatedpulmonaryhypertension
AT shuichitanoue sarcoidosisassociatedpulmonaryhypertension
AT tomoakihoshino sarcoidosisassociatedpulmonaryhypertension
AT tatsuyaishitake sarcoidosisassociatedpulmonaryhypertension
AT yoshihirofukumoto sarcoidosisassociatedpulmonaryhypertension